Company intelligence / Profile preview

Immunis.AI

Royal Oak, Michigan, USAimmunis.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

Immunis.AI has validated its non-invasive blood-based liquid biopsy platform for risk stratification in prostate cancer patients. Published clinical data demonstrate that the test can accurately identify aggressive disease comparable to invasive tissue biopsies. The company is preparing to commercialize this assay as a laboratory-developed test (LDT) in the US and Europe. Additional prospective studies are underway or completed for broader applications including multi-cancer early detection.

Therapeutic areas: Oncology
Modalities: Liquid biopsyBlood-based diagnosticsAI/ML-driven immunogenomics
Industry: Molecular Diagnostics

Partnerships

AWS/Amazon Web Services – cloud infrastructure partner[4]Ongoing collaborations with multiple academic sites for clinical validation[5]

Beyond the preview

Go deeper on Immunis.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunis.AI.

Explore the full profile